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Abstract 19 
Specific variations in the amino acid sequence of prion protein (PrP) are key 20 
determinants of susceptibility to prion diseases. We previously showed that an amino acid 21 
substitution specific to canids confers resistance to prion diseases when expressed in 22 
mice, and demonstrated its dominant-negative protective effect against a variety of 23 
infectious prion strains of different origins and characteristics. Here, we show that 24 
expression of this single amino acid change significantly increases survival time in 25 
transgenic mice expressing bank vole cellular prion protein (PrPC), which is inherently 26 
prone to misfolding, following inoculation with two distinct prion strains (the CWD-vole 27 
strain and an atypical strain of spontaneous origin). This amino acid substitution hinders 28 
the propagation of both prion strains, even when expressed in the context of a PrPC 29 
uniquely susceptible to a wide range of prion isolates. Non-inoculated mice expressing 30 
this substitution experience spontaneous prion formation, but showing an increase in 31 
survival comparable to that observed in mutant mice inoculated with the atypical strain.  32 
Our results underscore the importance of this PrP variant in the search for molecules with 33 
therapeutic potential against prion diseases.  34 
Keywords: Prions; Prion propagation; transmissible spongiform encephalopathies; 35 
canine PrP; bank vole PrP 36 
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Introduction 37 
Prions are self-propagating infectious proteins that cause fatal neurodegenerative 38 
disorders known as transmissible spongiform encephalopathies (TSE) or prion diseases. 39 
Characterized by spongiform changes, gliosis, and neuronal degeneration in the central 40 
nervous system (CNS), these diseases include scrapie in sheep and goats, bovine 41 
spongiform encephalopathy (BSE) in cattle, chronic wasting disease (CWD) in cervids, 42 
and Creutzfeldt-Jakob disease (CJD) in humans [1,2]. While the underlying trigger can 43 
be sporadic, genetic, or infectious in origin [3], the characteristic event in the pathogenesis 44 
of these diseases is misfolding of normal cellular prion protein (PrPC), giving rise to a 45 
protease-resistant, β-sheet-rich isoform known as PrPSc, which accumulates in the CNS 46 
leading to neurodegeneration [4].  47 
The presence of aspartic acid (D) at codon 163 of PrPC, a polymorphism exclusive 48 
to the Canidae family [5], may account for the unusual resistance of canid species to prion 49 
diseases [6]. Studies of recombinant proteins exposed to denaturing agents and in vitro 50 
and in vivo prion propagation studies assessing the susceptibility of species historically 51 
considered prion-resistant (leporids, equids, and canids) have demonstrated that canid 52 
PrPC shows the greatest resistance to misfolding [7-11]. Bank voles (Myodes glareolus), 53 
by contrast, are highly susceptible to prion infection, and have been used widely in prion 54 
research owing to their ability to efficiently propagate a broad spectrum of prion strains 55 
[12-16]. Bank vole PrPC is polymorphic, and either methionine (M) or isoleucine (I) can 56 
be expressed at codon 109 [17]. The adaptation of CWD in voles expressing isoleucine 57 
at codon 109 led to the isolation of the fastest prion strain (survival time, ∼35 days) 58 
identified to date [16]. Interestingly, overexpression of bank vole I109 PrP in transgenic 59 
mice leads to the development of spontaneous TSE, providing a very useful model for the 60 
study of sporadic prion diseases [18]. Given that sporadic forms are the most common 61 
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prion diseases in humans, and their origin remains unknown, the generation of these 62 
models is essential for research. It has been suggested that sporadic prion diseases may 63 
be caused by random and stochastic misfolding of PrPC, resulting in the accumulation of 64 
PrPSc and consequent clinical and neuropathological features associated with prion 65 
disorders [19].  66 
The canid D163 PrPC polymorphism is likely the main determinant of Canidae 67 
resistance to prion diseases. Indeed, the presence of this single substitution in mouse PrPC 68 
(N158D substitution in mouse PrPC numbering) prevents prion propagation both in vitro 69 
and in vivo [6]. We previously demonstrated that in vivo coexpression of the N158D PrPC 70 
variant and wild-type mouse PrPC significantly delays disease onset in transgenic mice 71 
inoculated with several prion strains of different origins and characteristics [20], 72 
suggesting that N158D PrPC is a promising candidate in the search for proteins with 73 
dominant-negative effects against a broad spectrum of prion strains. In the present study, 74 
we investigated whether this substitution could also prevent or delay the onset of prion 75 
disease in a highly susceptible model. Transgenic mice overexpressing bank vole I109 76 
PrP and carrying this specific residue (TgVole-N159D mice), were inoculated with two 77 
prion isolates, and the resulting survival times compared with those of transgenic mice 78 
expressing comparable levels of bank vole PrPC (TgVole mice) but lacking this PrPC 79 
residue. To corroborate the ability of this amino acid substitution to confer protection 80 
against prion propagation, we used two distinct strains with very different 81 
neuropathological and biochemical features. For both inoculated prion strains, survival 82 
periods in TgVole-N159D mice were 52–108% longer than those of TgVole mice. These 83 
results are in good agreement with our previous findings demonstrating that expression 84 
of this specific amino acid substitution, even when expressed in a PrPC highly susceptible 85 
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to misfolding, interferes with prion propagation and delays the onset of disease caused by 86 
multiple, distinct prion strains.  87 
Materials and Methods 88 
Ethics statement 89 
All procedures involving animals were approved by the University of Zaragoza’s 90 
Ethics Committee for Animal Experiments (permit number PI32/13) and were performed 91 
in accordance with recommendations for the care and use of experimental animals and 92 
with Spanish law (R.D. 1201/05). 93 
Inoculation of transgenic mice and sample processing  94 
Two different transgenic mouse models were used in the present study: transgenic 95 
mice expressing ∼3-4x the I109 polymorphic variant of bank vole PrP and carrying the 96 
critical dog amino acid substitution (I109-N159D PrPC), hereafter referred to as TgVole-97 
N159D mice, and mice overexpressing ∼3-4x bank vole I109 PrPC, hereafter referred to 98 
as TgVole mice, which were used as controls. The murine PRNP promoter was used for 99 
both I109-N159D and I109 PrPC expression, in a murine Prnp0/0 background. Mice were 100 
generated and characterized as previously described [21].  101 
Mice were anesthetized with isoflurane and intracerebrally inoculated (right 102 
cerebral hemisphere) with 20 µl of a 1 % brain homogenate. Both TgVole-N159D and 103 
TgVole mice were inoculated with one of two different isolates: CWD-vole, a CWD 104 
strain adapted to bank voles that contains I109 PrP and is characterized by very short 105 
survival times [16]; and an atypical prion isolate (Sp-TgVole isolate) of spontaneous 106 
origin. Sp-TgVole inoculum was obtained from brain homogenates from TgVole mice 107 
[22] that were sacrificed at 182±5 days of age after developing a spontaneous 108 
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neurodegenerative disorder linked to the overexpression of the I109 variant of bank vole 109 
PrP [18] (Supplementary Fig. 1). Intracerebral injections were performed using a 50-µl 110 
precision syringe and a 25-G needle. After inoculation, mice received a subcutaneous 111 
injection of buprenorphine (0.3 mg/kg) to induce analgesia.   112 
Mice were monitored for the onset of neurologic signs after inoculation, sacrificed 113 
by cervical dislocation upon detection of clinical signs of terminal disease (i.e., severe 114 
locomotor disorders, poor body condition, and any signs of impaired feeding ability), and 115 
their brains collected. Coronal sections were cut at the level of the frontal cortex and 116 
medulla oblongata and immediately stored at -80 ºC for biochemical analyses. The 117 
remaining brain tissue was stored in 10 % formalin fixative for histological analyses. 118 
Histopathological evaluation  119 
Formalin-fixed brains were sectioned transversely at four standard levels for 120 
neuropathological analyses of the following brain areas: frontal cortex (Fc), septal area 121 
(Sa), thalamic cortex (Tc), hippocampus (Hc), thalamus (T), hypothalamus (Ht), 122 
mesencephalon (Mes), cerebellar cortex (Cbl), and medulla oblongata (Mo) [23]. 123 
Formalin-fixed brain tissues were embedded in paraffin wax, and 4-µm-thick tissue 124 
sections were mounted on microscope slides for hematoxylin-eosin staining. The 125 
intensity and distribution of spongiform changes were blindly evaluated using an optical 126 
microscope (Zeiss Axioskop 40) and semiquantitatively scored on a scale of 0 (absence 127 
of lesions) to 5 (high intensity lesions) in each of the aforementioned brain regions.   128 
Analysis of PrPSc deposition 129 
The detection of PrPSc deposition in paraffin-embedded brains was performed 130 
using the paraffin-embedded tissue (PET) blot technique, as previously described [24,25]. 131 
PrPSc was detected by incubation with the Sha31 primary monoclonal antibody (1:8,000; 132 
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SPI-Bio), followed by an alkaline phosphatase-coupled goat anti-mouse antibody (1:500; 133 
Dako). Immunolabeling was visualized using the NBT/BCIP substrate chromogen (nitro 134 
blue tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate; Sigma-Aldrich). The presence, 135 
intensity, and distribution of PrPSc aggregates were evaluated using a Zeiss Stemi DV4 136 
stereomicroscope and semiquantitatively scored as described for spongiform lesions.  137 
The distribution of PrPSc deposition was also analyzed by immunohistochemistry 138 
using a previously described protocol [26], with some modifications. Paraffin-embedded 139 
sections were pre-incubated with 98 % formic acid for 5 min and underwent hydrated 140 
autoclaving in citrate buffer for 20 min at 96 ºC. Peroxidase activity was blocked for 5 141 
min using a peroxidase blocking reagent (Dako). Immunodetection of PrPSc was achieved 142 
by incubation with 6H4 monoclonal antibody (1:100, Prionics) followed by an anti-mouse 143 
Envision polymer (Dako). Sections were subsequently incubated with DAB 144 
(diaminobenzidine, Dako) and counterstained with hematoxylin.  145 
Biochemical analysis of inoculated strains 146 
 Proteinase K (PK) resistant PrPSc was detected and characterized in both the 147 
CWD-vole and Sp-TgVole inocula before inoculation. To this end, 10 % brain 148 
homogenates from CWD-vole I109 inoculated animals (CWD-vole strain) were 149 
incubated with 80 μg/ml PK for 1 h at 42 ºC with constant agitation (450 rpm), as 150 
previously described [27]. Biochemical characterization of spontaneously generated 151 
TgVole I109 prions (Sp-TgVole strain) was also carried out as reported previously [28]. 152 
Briefly, brain homogenates (20% w/v) from clinically diseased animals were mixed with 153 
an equal volume of 100 mM Tris-HCl + 4 % sarkosyl and incubated for 30 min at 37 ºC. 154 
Homogenates were then digested with 200 μg/ml PK (Sigma-Aldrich) for 1 h at 55 ºC 155 
with gentle agitation. Aliquots of samples were mixed with an equal volume of 156 
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isopropanol/butanol (1:1 v/v) and centrifuged for 5 min at 20,000 × g. Supernatants were 157 
discarded and pellets were re-suspended in denaturing sample buffer (NuPage). Both 158 
CWD-vole and Sp-TgVole inocula were analyzed by Western blotting using the 12B2 159 
antibody (1:2,500), which recognizes the 89–93 epitopes of bank vole PrP. 160 
Histological analysis of PrP distribution 161 
The histological localization and distribution of cellular PrP in the brains of both 162 
TgVole-N159D and TgVole mice was analyzed by immunohistochemistry as previously 163 
described [20]. Briefly, paraffin-embedded brain sections were incubated with a 1% 164 
peroxidase solution for 20 min followed by hydrated autoclaving at 100°C in citrate 165 
buffer for 30 min. PrP immunodetection was performed overnight at 4°C using SAF84 166 
(1:1,000; Cayman Chemical) antibody. The anti-mouse Envision polymer (Dako) was 167 
used as the visualization system and DAB (diaminobenzidine, Dako) as the chromogen.   168 
 The cellular localization of PrP was further analyzed in the brains of TgVole-169 
N159D and TgVole mice using immunofluorescence and confocal imaging. The 170 
immunofluorescence staining was performed as described previously [20]. Paraffin-171 
embedded tissue sections from TgVole-N159D and TgVole mice were pre-treated with 172 
1% peroxidase for 30 min. Sections were subsequently permeabilized with 0,1% Triton 173 
X-100 for 3 h at room temperature and subjected to hydrated autoclaving. 174 
Immunodetection was carried out with SAF84 antibody (1:1000) followed by a goat anti-175 
mouse IgG biotin conjugate (1:100; Invitrogen) and an Alexa fluor 594 streptavidin 176 
conjugate (1:1000; Invitrogen). Sections were observed under a Zeiss laser-scanning 177 
confocal microscope LSM 510 (Carl Zeiss MicroImaging). 178 
Data analysis 179 
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Survival times were analyzed using the Kaplan-Meier method and the survival 180 
curves for mice carrying the N159D substitution were compared with those of controls 181 
using the log rank test (α= 0.05). Differences in histopathological and PrPSc deposition 182 
profiles between transgenic mouse models were analyzed using the nonparametric Mann-183 
Whitney U-test, with p-values <0.05 considered significant. GraphPad Prism version 6.0 184 
(GraphPad Software, La Jolla, CA, USA) was used for data analysis and to generate 185 
Kaplan Meier curves and histopathology graphs. 186 
Results 187 
Expression of the N159D PrPC substitution markedly increases survival time in 188 
mice challenged with the CWD-vole and Sp-TgVole strains  189 
Transgenic mice expressing bank vole I109 PrPC and carrying the prion 190 
resistance-associated N159D amino acid substitution (TgVole-N159D mice) were 191 
intracerebrally inoculated with either the classical CWD-vole strain or the atypical Sp-192 
TgVole strain (Supplementary Fig. 1). As controls, TgVole mice expressing comparable 193 
levels of bank vole I109 PrPC (∼3-4×) were challenged with the same isolates. Both 194 
transgenic lines present a normal cellular distribution of PrP through the brain and show 195 
a good expression of PrP in the cellular membrane (Supplementary Fig. 2). After 196 
challenge with the CWD-vole strain, survival time in TgVole-N159D mice was 108 % 197 
longer than that of control TgVole mice, in which the mean survival time was 61±4 days 198 
post-inoculation (dpi). In TgVole-N159D mice inoculated with the Sp-TgVole isolate, 199 
survival time was 52 % longer than that of control TgVole mice (Table 1).  200 
In both the TgVole and TgVole-N159D transgenic mice, overexpression of bank 201 
vole I109 PrPC (∼3-4x) leads to the development of a spontaneous neurodegenerative 202 
disorder. However, TgVole-N159D mice develop the spontaneous form of the disease 203 
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showing an increase in survival time of 60 % relative to non-inoculated TgVole animals 204 
(Table 1). This relative increase in survival is comparable to that observed in TgVole-205 
N159D mice inoculated with the Sp-TgVole strain. For both inoculated strains, survival 206 
time was significantly longer in TgVole-N159D versus TgVole mice (Fig. 1). Significant 207 
differences in survival were obtained between TgVole-N159D and TgVole mice for both 208 
strains inoculated and between non-inoculated, spontaneously sick TgVole-N159D and 209 
TgVole mice (Fig. 1).  210 
Despite the significant delay in disease onset, TgVole-N159D mice exhibited 211 
clinical signs of neurodegeneration identical to those seen in TgVole mice. Animals 212 
inoculated with the CWD-vole strain exhibited dorsal kyphosis, circling behavior, 213 
cachexia, and tremor. By contrast, those inoculated with the Sp-TgVole isolate showed 214 
mild kyphosis and rapidly progressing ataxia.215 
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Table 1. Survival periods of TgVole and TgVole-N159D mice. 216 
 217 
 218 
a Data based on PrPSc detection. 219 
b Survival times were calculated as the number of days between inoculation and sacrifice of mice 220 
inoculated with CWD-vole or Sp-TgVole isolates, provided that the mouse developed clinical 221 
signs consistent with a TSE. Survival times are expressed as the mean (± SEM) number of dpi. 222 
 c For non-inoculated mice survival times were considered as the mean age at which the animals 223 
sporadically developed clinical signs consistent with a TSE and were euthanized. The age at 224 
which animals succumbed to disease is expressed as mean (± SEM) days of age. 225 
SEM, standard error of the mean; dpi, days post-inoculation; NA, not applicable. 226 
d Prolongation of survival time in TgVole-N159D mice is expressed as the percentage increase in 227 
mean survival time relative to TgVole mice. 228 
e One animal from the group inoculated with CWD-vole isolate group died during the initial stages 229 
of the study due to a concomitant disease. This animal exhibited no spongiform lesions or PrPSc 230 
deposits and was excluded from all analyses.  231 
   
Inoculum Model Attack ratea Survival time 
(mean ± SEM)b 
Age at which 
animals 
succumbed to 
disease c 
Relative increase in survival time 
(%)d 
CWD-vole 
TgVole 5 e /5 (100%) 61 ± 4 143 ± 5 - 
TgVole-N159D 6/6 (100%) 127 ± 13 205 ± 12 108% 
Sp-TgVole 
TgVole 7/7 (100%) 120 ± 9 178 ± 6 - 
TgVole-N159D 5 /5 (100%) 182 ± 3 247 ± 6 52% 
Non-inoculated  
TgVole 10/10 (100%) - 182 ± 5 - 
TgVole-N159D 12/12 (100%) - 292 ± 10 60% 
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 232 
Figure 1. Survival curves for TgVole and TgVole-N159D mice (non-inoculated or after 233 
challenge with CWD-vole or Sp-TgVole isolates). Analysis of survival curves using the log 234 
rank test (α=0.050) revealed significant differences between TgVole and TgVole-N159D mice 235 
after inoculation with either CWD-vole (p=0.0007) or Sp-TgVole (p=0.0011) isolates, and 236 
between non-inoculated TgVole and TgVole-N159D mice (p<0.0001) that developed 237 
spontaneous forms of the disease. Survival periods are expressed as days post-inoculation (dpi) 238 
for inoculated groups, and as days of age at which mice succumbed to the spontaneous TSE for 239 
non-inoculated groups. 240 
 241 
Expression of the N159D substitution does not alter the neuropathological features 242 
of the disease 243 
Expression of the PrPC N159D substitution, a key amino acid substitution 244 
associated with prion disease resistance in dogs [6], considerably delayed the onset of 245 
clinical signs, but did not significantly alter the neuropathological features exhibited by 246 
TgVole-N159D mice. Similar results were observed in our previous study, in which the 247 
effects of this dog-specific substitution were studied in the mouse PrP backbone [20].  248 
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Semi-quantitative analysis of spongiosis and prion protein deposition patterns in 249 
9 brain areas revealed no significant differences between TgVole-N159D and TgVole 250 
mice inoculated with the same isolate (Fig. 2). All mice inoculated with the CWD-vole 251 
strain showed moderate spongiform changes and discretely distributed PrPSc deposits, 252 
which were particularly conspicuous in the thalamus. In other brain regions, such as the 253 
hippocampus, spongiosis was minimal and PrPSc deposition scores were very low (Figs. 254 
2 and 3). These neuropathological features coincide with those described in I109 bank 255 
voles infected with the same strain, in which prominent involvement of the thalamus has 256 
been reported [16]. Moreover, both TgVole-N159D and TgVole mice inoculated with the 257 
atypical Sp-TgVole isolate exhibited severe vacuolar changes in the cortex (Fc and Tc) 258 
and in the hippocampus, in which we observed the most intense PrPSc deposition for this 259 
isolate (Figs. 2 and 3). To verify that the Sp-TgVole strain maintained its 260 
neuropathological characteristics after experimental transmission to TgVole and TgVole-261 
N159D mice, we performed a histopathological assessment of brain samples from TgVole 262 
and TgVole-N159D animals that spontaneously developed the disease at ∼182 and ∼292 263 
days of age, respectively. The lesion profiles and PrPSc deposition patterns in these 264 
animals were almost identical to one another and to those of mice inoculated with the Sp-265 
TgVole isolate (Fig. 2). 266 
The fact that similar neuropathological features were observed in TgVole and 267 
TgVole-N159D mice inoculated with the Sp-TgVole strain, and in non-inoculated 268 
TgVole mice, suggests the development of the same spontaneous disease in these 269 
inoculated mice in an accelerated or induced manner.  270 
 271 
 272 
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 273 
 274 
Figure 2. Spongiosis and PrPSc deposition profiles in the brains of TgVole and 275 
TgVole-N159D mice inoculated with CWD-vole or Sp-TgVole prion isolates, or non 276 
inoculated. Spongiosis and PrPSc deposition were evaluated semiquantitatively on a scale 277 
of 0 (absence of lesions/deposits) to 5 (high intensity lesions/deposition) in the following 278 
nine brain areas: frontal cortex (Fc), septal area (Sa), thalamic cortex (Tc), hippocampus 279 
(Hc), thalamus (T), hypothalamus (Ht), mesencephalon (Mes), cerebellum (Cbl), and 280 
medulla oblongata (Mo). Graphs represent the mean with SEM of at least 5 mice per 281 
group. Comparison of the lesion and PrPSc deposition profiles of TgVole and TgVole-282 
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N159D mice revealed no significant differences between groups for any parameter 283 
(α=0.05, Mann-Whitney U test). 284 
 285 
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Figure 3.  a PET blot images of coronal brain sections from TgVole and TgVole-286 
N159D mice inoculated with CWD-vole or Sp-TgVole isolates. The distribution 287 
pattern of PrPSc deposition (dark purple) in mice expressing the N159D substitution is 288 
very similar to that of non-inoculated TgVole controls. Animals inoculated with the Sp-289 
TgVole strain show marked PrPSc deposition in the hippocampus. By contrast, in CWD-290 
vole-inoculated animals immunolabelling with the Sha31 antibody is much weaker in the 291 
hippocampus, and strongest in the thalamus. b Immunohistochemical analysis of a 292 
TgVole mouse with the spontaneous form of the disease and of TgVole-N159D and 293 
TgVole mice inoculated with the Sp-TgVole strain. Note that the morphology and 294 
distribution of PrPSc deposits is almost identical in the three mice, all of which show 295 
abundant granular PrPSc deposition in the dentate gyrus and in Ammon’s horn of the 296 
hippocampus. Immunodetection was performed using the 6H4 monoclonal antibody 297 
(1:100). 298 
Discussion 299 
The role in prion disease resistance of certain naturally occurring variants in the 300 
amino acid sequence of PrPC has been intensively studied. The presence of at least one 301 
arginine at codon 171 in sheep PrPC appears to confer low susceptibility to classical 302 
scrapie infection [29,30]. Studies have demonstrated that this single amino acid 303 
substitution exerts a dominant-negative inhibitory effect on prion replication both in vitro 304 
and in vivo [31-34]. Heterozygosity for specific human PrPC polymorphisms also protects 305 
against acquired, sporadic, and some familial prion diseases [35,36]. The resistance-306 
associated human polymorphisms E219K and G127V not only confer strong protection 307 
against human prion diseases, but also exert a dominant-negative inhibitory effect on 308 
prion propagation when coexpressed with wild-type prion protein [36,33,37]. 309 
Introduction of these naturally occurring single mutations into an exogenous PrPC 310 
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therefore represents a potential therapeutic strategy [33,37]. However, when searching 311 
for dominant-negative PrPs it is important to bear in mind that susceptibility to TSE 312 
depends on both the PRNP genotype and the infectious strain [38,39]. Although strong, 313 
the resistance to prion propagation conferred by most of these polymorphisms is strain-314 
specific [40-42]. In this study, we investigated the potential protective effect of the D163 315 
(D159 in bank vole numbering) PrPC residue. This amino acid is almost exclusive to canid 316 
species [5,6], in which no naturally occurring TSE have been described. Moreover, the 317 
PrPC form expressed by these species is highly resistant to misfolding in vitro [7] and 318 
appears not to undergo misfolding in vivo [6,8]. 319 
We previously demonstrated that mice overexpressing a mutated prion protein 320 
carrying the N158D amino acid substitution are completely resistant to prion infection 321 
when inoculated with a variety of mouse-adapted prion strains [6]. Moreover, we have 322 
shown that coexpression of wild-type mouse PrPC and a mutant PrPC variant carrying this 323 
specific dog amino acid substitution has a dominant-negative effect on the in vivo 324 
propagation of mouse-adapted prion strains of scrapie and BSE origins [20]. However, 325 
could this amino acid substitution, characteristic of the most resistant mammalian species, 326 
prevent the misfolding of a PrPC characterized by an extraordinary promiscuity to 327 
propagate numerous prion strains [15]?  328 
Here, we show that in mice overexpressing bank vole PrPC I109, whose 329 
misfolding ability is such that its single overexpression leads to the development of a 330 
spontaneous prion disease [18], the presence of the N159D substitution in PrPC 331 
significantly delays the onset of clinical signs. These findings suggest that the protective 332 
effect of this amino acid change characteristic of canids is stronger when expressed in 333 
mouse PrPC [6]. Although non-inoculated TgVole-N159D mice present a delay in the 334 
onset of clinical signs, we have observed that the expression of this resistance-associated 335 
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substitution does not prevent spontaneous prion formation in these animals. However, it 336 
is important to remember that bank vole PrPC is greatly prone to conversion and allows 337 
the propagation of prion strains which are refractory to be transmitted in wild-type and 338 
transgenic mice. [12,14,43]. Bank voles expressing the I109 polymorphic variant of PrPC 339 
are more susceptible to certain familial prion disorders than transgenic mice 340 
overexpressing homologous PrP carrying the corresponding mutation that causes the 341 
disease in humans [14,44]. However, we show that the N159D substitution can increase 342 
survival time in a model that overexpresses a form of PrPC that is highly susceptible to 343 
misfolding induced by almost all prion strains. The prolongation of survival time was 344 
especially striking in TgVole-N159D mice after inoculation with the classical CWD-vole 345 
prion strain, which is the prion strain causing the shortest survival times described to date 346 
[16]: survival time in these mice was 108% longer than that of TgVole mice. While a 347 
significant increase in survival time was also observed in TgVole-N159D mice inoculated 348 
with Sp-TgVole isolate, an atypical strain of spontaneous origin, this effect was less 349 
marked than that observed for the CWD-vole strain (Table 1). Thus, the protective effect 350 
of the N159D substitution, although considerable in all cases, appears not to be 351 
homogeneous across strains. This observation is in good agreement with our previous 352 
findings in mice coexpressing the protein carrying the dog-specific substitution, in which 353 
the mutated protein inhibited prion propagation in a strain-specific manner [20]. It could 354 
be discussed, however, that comparing a single transgenic line carrying the mutation 355 
(TgVole-N159D mice) with a single control line (TgVole mice) is a too straightforward 356 
approach to evaluate the protective effect of the substitution. We generated other mutated 357 
lines, but their PrP expression levels were not comparable with those of their 358 
corresponding controls. Nevertheless, the goal of the present study is to analyze the 359 
transmission barrier to TgVole-N159D mice, and we consider that the most important 360 
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parameters determining that transmission are the PrP expression level and the distribution 361 
of PrP. TgVole-N159D and TgVole transgenic lines have a normal cellular distribution 362 
of PrP (Supplementary figure 2) and they show no differences between PrP expression 363 
levels or electrophoretic migration patterns (Figure 3). Therefore, we believe that the 364 
comparison between these lines is a suitable way to evaluate the effect of the N-to-D 365 
substitution.    366 
Analysis of neuropathological features in TgVole-N159D and TgVole mice 367 
revealed no significant differences in lesional or PrPSc deposition profiles (Fig. 2). All 368 
mice inoculated with the Sp-TgVole isolate, generated by spontaneous misfolding of I109 369 
PrPC, showed near identical neuropathological profiles. This profile was clearly 370 
distinguishable from that of mice inoculated with the CWD-vole strain (Figs. 2 and 3). 371 
The distribution and morphology of PrPSc deposition in mice inoculated with the Sp-372 
TgVole isolate was comparable to that of TgVole-N159D and TgVole mice that 373 
developed spontaneous forms of the disease (Fig. 2 and 3b). However, it should be borne 374 
in mind that non-inoculated TgVole-N159D and TgVole mice develop spontaneous TSE. 375 
Therefore, once they have exceeded the age at which this spontaneous disorder develops, 376 
it cannot be determined with certainty whether the observed neuropathology is a result of 377 
this phenomenon or a consequence of inoculation. Comparison of age at disease onset 378 
revealed that mice inoculated with the Sp-TgVole isolate succumbed to disease at a 379 
younger age than non-inoculated TgVole-N159D and TgVole mice (Table 1). Inoculation 380 
of the Sp-TgVole isolate thus appears to cause a seeding acceleration phenomenon, i.e., 381 
the spontaneous pathological process characteristic of the model is accelerated by 382 
exogenous inoculation of the isolate [45]. Similar findings were reported in a study using 383 
transgenic mice overexpressing bank vole I109 prion protein [18]; inoculation of brain 384 
extracts from spontaneously diseased mice accelerated disease onset, reproducing the 385 
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neuropathological hallmarks seen in transgenic mice expressing the same transgene. 386 
Moreover, as mentioned, expression of the substitution did not impede the spontaneous 387 
generation of the prion, and TgVole-N159D mice experimented an increase in survival 388 
similar to that of Sp-TgVole inoculated animals. These results agree with the suggestion 389 
that the effects of the N159D substitution are strain-dependent, and that both non-390 
inoculated and Sp-TgVole inoculated mice propagate the same strain. In addition, it could 391 
be discussed that the delay in the onset of clinical signs observed in Sp-TgVole inoculated 392 
TgVole-N159D mice could be associated with the fact that this isolate was obtained from 393 
spontaneously sick TgVole animals. Thus, it could be possible that Sp-TgVole isolate is 394 
more adapted to the TgVole model. However, we should consider that non-inoculated 395 
TgVole-N159D mice show an almost identical delay in the onset of the disease. 396 
Moreover, in a parallel experiment, we inoculated brain homogenates from spontaneously 397 
sick TgVole-N159D mice in TgVole and TgVole-N159D mice. We observed again that 398 
TgVole-N159D inoculated mice presented a survival period ~50% longer than TgVole 399 
animals (data not shown); although the isolate was obtained from TgVole-N159D mice 400 
and could therefore be better adapted to this model.   We can conclude that while 401 
expression of the resistance-associated amino acid change significantly increased survival 402 
times, it did not alter the pathological features of the inoculated strains. These results are 403 
in agreement with our previous findings [20], and suggest that the delayed appearance of 404 
clinical signs in TgVole-N159D mice is not caused by strain modifications resulting from 405 
the N159D substitution.   406 
The precise molecular mechanisms by which the N159D substitution prolongs 407 
survival time in TgVole-N159D mice remain unclear. However, this residue can extend 408 
the survival period in both inoculated mice and those that develop spontaneous disease, 409 
as evidenced by the significant differences in survival time between TgVole (182±5 days) 410 
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and TgVole-N159D mice (292±10 days) with spontaneous disease (Table 1 and Fig. 1). 411 
Several theories have been proposed to explain the molecular basis of the anti-prion 412 
propagation effect of certain single amino acid changes in PrPC. We previously described 413 
the fully protective effect of the N-to-D substitution in mouse PrP against prion 414 
inoculation [6], and the dominant negative effect of this protective mutation [20]. It has 415 
been suggested that coexpression with wild-type PrP of certain heterologous PrPs 416 
carrying putative protective mutations may interfere with the interaction between similar 417 
PrP monomers [46-48]. This interference could potentially disrupt the mechanism by 418 
which PrPC is converted into PrPSc [48], since allelic variants can be structurally 419 
incompatible [49]. In fact, this disruptive effect has been tested as a potential anti-prion 420 
therapy both in vitro [50] and in vivo [51], with successful results. Furthermore, the 421 
introduction of single point mutations, and the heterologous interference they cause, has 422 
also been proposed to account for the long survival periods observed when a prion strain 423 
is transmitted to a new host [48]. The N159D substitution may exert a protective effect 424 
by inducing protein alterations that attenuate the rate of fibril formation and the stability 425 
of newly formed fibrils [6]. This molecular mechanism has been previously proposed for 426 
other PrPC amino acid substitutions [52,37]. In fact, it has been shown that the protective 427 
human PrPC variant G127V, which also acts as a dominant-negative protein [37], hinders 428 
the formation of dimers and stable fibrils, thereby protecting against the development of 429 
prion diseases [53]. Given that the N-to-D substitution at this specific position 430 
significantly alters the surface charge of PrP [6], the N159D substitution may have a 431 
similar effect in the context of bank vole PrPC.  432 
The results presented here indicate that the introduction of a specific canid N-to-433 
D amino acid substitution into exogenously administered PrPC not only confers complete 434 
resistance to TSE in certain mouse models but also significantly increases survival times 435 
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in models overexpressing PrPs that are highly susceptible to misfolding. Moreover, the 436 
N159D substitution delays the onset of clinical signs of both infectious and spontaneous 437 
forms of prion diseases. Together with our previous findings demonstrating a dominant-438 
negative effect of prion protein carrying the N-to-D substitution against a variety of prion 439 
strains of different origins [20], we can conclude that this mutation could represent a 440 
useful tool to control the propagation of different prion strains when present in the correct 441 
PrP background.  442 
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Supplementary material 644 
 645 
Supplementary Figure 1. Biochemical analyses of the two inoculated prion strains. 646 
Biochemical analysis of proteinase-K (PK)-resistant PrPSc in brain homogenates from 647 
I109 TgVole mice inoculated with the CWD-vole strain and from spontaneously 648 
generated TgVole I109 PrPSc (Sp-TgVole strain). Representative brain homogenates were 649 
digested with 80 µg/ml and 200 µg/ml of PK, respectively. Samples were run in the 650 
different gels, as indicated by the grey line. CWD-vole strain shows a classical 651 
electrophoretic pattern. By contrast, the spontaneously generated TgVole I109 prion 652 
strain results in accumulation of atypical prions, characterized by an electrophoretic 653 
migration pattern similar to that observed in human GSS, with a predominant 7–10-kDa 654 
PK-resistant band. 12B2 monoclonal antibody (1:2,500). Control, undigested TgVole 655 
whole brain homogenate. MW, molecular weight.  656 
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 657 
Supplementary Figure 2: Histological localization of PrP in TgVole and TgVole-658 
N159D mouse brains. a Immunohistochemical detection of PrP in medulla oblongata 659 
from a TgVole and a TgVole-N159D mouse using SAF84 monoclonal antibody. Both 660 
animals show a normal neuroanatomic distribution of PrP presenting intense 661 
immunoreactivity in the neuronal bodies.  662 
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 b TgVole and TgVole-N159D brain serial optical z-sections by confocal microscopy 663 
(x20). To determine the cellular localization of  PrP in the transgenic lines used, the 664 
fluorescence emission from a TgVole and a TgVole-N159D mouse brain was analyzed 665 
by confocal microscopy. The fluorescence emission resulted from excitation with 594-666 
nm laser and was detected using long-pass 615-nm filter. 0,5 µm z-stacks of digital 667 
images were captured using Zen 2008 software (Carl Zeiss Microimaging) with 20x (NA 668 
1.3) objective. Both animals present a very intense neuronal staining for PrP, which was 669 
detected in the neuronal membrane (arrows). (SAF84 antibody, 1:1000).  670 
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